{"result": {"id": "c1454b54-cde5-4c0a-9e58-378a3b6f292c", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "(\"entity\"<|>富马酸比索洛尔<|>organization<|>A pharmaceutical component used in combination with other drugs for treating hypertension and related conditions)\n##\n(\"entity\"<|>苯磺酸氨氯地平<|>organization<|>A pharmaceutical component used in combination with other drugs for treating hypertension and related conditions)\n##\n(\"entity\"<|>尼群地平<|>organization<|>A pharmaceutical component used in combination with other drugs for treating hypertension and related conditions)\n##\n(\"entity\"<|>阿替洛尔<|>organization<|>A pharmaceutical component used in combination with other drugs for treating hypertension and related conditions)\n##\n(\"entity\"<|>复方阿米洛利<|>organization<|>A combination drug used for treating hypertension, containing Amiloride and Hydrochlorothiazide)\n##\n(\"entity\"<|>阿米洛利<|>organization<|>A pharmaceutical component used in combination with other drugs for treating hypertension and related conditions)\n##\n(\"entity\"<|>氢氯噻嗪<|>organization<|>A pharmaceutical component used in combination with other drugs for treating hypertension and related conditions)\n##\n(\"entity\"<|>复方利血平片<|>organization<|>A combination drug used for treating hypertension, containing Reserpine, Hydrochlorothiazide, Dihydralazine, and Promethazine)\n##\n(\"entity\"<|>利血平<|>organization<|>A pharmaceutical component used in combination with other drugs for treating hypertension and related conditions)\n##\n(\"entity\"<|>双肼屈嗪<|>organization<|>A pharmaceutical component used in combination with other drugs for treating hypertension and related conditions)\n##\n(\"entity\"<|>异丙嗪<|>organization<|>A pharmaceutical component used in combination with other drugs for treating hypertension and related conditions)\n##\n(\"entity\"<|>复方利血平氨苯蝶啶片<|>organization<|>A combination drug used for treating hypertension, containing Reserpine, Triamterene, Hydrochlorothiazide, and Dihydralazine)\n##\n(\"entity\"<|>氨苯蝶啶<|>organization<|>A pharmaceutical component used in combination with other drugs for treating hypertension and related conditions)\n##\n(\"entity\"<|>珍菊降压片<|>organization<|>A combination drug used for treating hypertension, containing Clonidine and Hydrochlorothiazide)\n##\n(\"entity\"<|>可乐定<|>organization<|>A pharmaceutical component used in combination with other drugs for treating hypertension and related conditions)\n##\n(\"entity\"<|>依那普利/叶酸片<|>organization<|>A combination drug used for treating hypertension, containing Enalapril and Folic Acid)\n##\n(\"entity\"<|>依那普利<|>organization<|>A pharmaceutical component used in combination with other drugs for treating hypertension and related conditions)\n##\n(\"entity\"<|>叶酸<|>organization<|>A pharmaceutical component used in combination with other drugs for treating hypertension and related conditions)\n##\n(\"entity\"<|>氨氯地平/叶酸片<|>organization<|>A combination drug used for treating hypertension, containing Amlodipine and Folic Acid)\n##\n(\"entity\"<|>氨氯地平<|>organization<|>A pharmaceutical component used in combination with other drugs for treating hypertension and related conditions)\n##\n(\"entity\"<|>氨氯地平/阿托伐他汀<|>organization<|>A combination drug used for treating hypertension and related conditions, containing Amlodipine and Atorvastatin)\n##\n(\"entity\"<|>阿托伐他汀<|>organization<|>A pharmaceutical component used in combination with other drugs for treating hypertension and related conditions)\n##\n(\"relationship\"<|>富马酸比索洛尔<|>苯磺酸氨氯地平<|>Combined in a single medication for treating hypertension<|>8)\n##\n(\"relationship\"<|>尼群地平<|>阿替洛尔<|>Combined in a single medication for treating hypertension<|>8)\n##\n(\"relationship\"<|>阿米洛利<|>氢氯噻嗪<|>Combined in a single medication for treating hypertension<|>8)\n##\n(\"relationship\"<|>利血平<|>氢氯噻嗪<|>Combined in a single medication for treating hypertension<|>8)\n##\n(\"relationship\"<|>利血平<|>双肼屈嗪<|>Combined in a single medication for treating hypertension<|>8)\n##\n(\"relationship\"<|>利血平<|>异丙嗪<|>Combined in a single medication for treating hypertension<|>8)\n##\n(\"relationship\"<|>利血平<|>氨苯蝶啶<|>Combined in a single medication for treating hypertension<|>8)\n##\n(\"relationship\"<|>可乐定<|>氢氯噻嗪<|>Combined in a single medication for treating hypertension<|>8)\n##\n(\"relationship\"<|>依那普利<|>叶酸<|>Combined in a single medication for treating hypertension<|>8)\n##\n(\"relationship\"<|>氨氯地平<|>叶酸<|>Combined in a single medication for treating hypertension<|>8)\n##\n(\"relationship\"<|>氨氯地平<|>阿托伐他汀<|>Combined in a single medication for treating hypertension and related conditions<|>8)\n<|COMPLETE|>", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1751558617, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 1205, "prompt_tokens": 2492, "total_tokens": 3697, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 1792}, "prompt_cache_hit_tokens": 1792, "prompt_cache_miss_tokens": 700}}, "input": {"messages": [{"content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: � ,踝部水肿 ,支气管痉挛 ,心动过缓\n富马酸比索洛尔 5 mg/苯磺酸氨氯地平 5 mg\t1\t1\t\n尼群地平/阿替洛尔\n尼群地平 10mg/阿替洛尔 20mg 尼群地平 5 mg/阿替洛尔 10mg\t\n　　1 1~2\t\n1~2 1~2\t头痛 ,踝部水肿 ,支气管痉挛 ,心动过缓\n\n\n续表 16\n\n主要组分与每片剂量                                                                      每天服药片数 每天服药次数                      主要不良反应\n复方阿米洛利\t血钾异常 ,尿酸升高\n阿米洛利 2. 5 mg/氢氯噻嗪 25mg\t1\t1\t\n复方利血平片\t\t\t消化性溃疡 , 困倦\n利血平 0. 032mg/氢氯噻嗪 3. 1 mg/双肼屈嗪 4. 2 mg/异丙嗪 2. 1 mg\t1~3\t2~3\t\n复方利血平氨苯蝶啶片\n利血平 0. 1 mg/氨苯蝶啶 12. 5 mg/氢氯噻嗪 12. 5 mg/双肼屈嗪 12. 5 mg\t\n1~2\t\n1~2\t消化性溃疡 ,头痛\n珍菊降压片\t\t\t低血压 ,血钾异常\n可乐定 0. 03mg/氢氯噻嗪 5 mg\t1~3\t2~3\t\n依那普利/叶酸片\n依那普利 10mg/叶酸 0. 8 mg\t\n1\t\n1\t咳嗽 ,恶心 ,偶见血管神经性水肿\n氨氯地平/叶酸片\t\t\t头晕 ,踝部水肿 ,恶心\n氨氯地平 5 mg/叶酸 0. 8 mg\t1\t1\t\n氨氯地平/阿托伐他汀\n氨氯地平 5 mg/阿托伐他汀 10mg 氨氯地平 5 mg/阿托伐他汀 20mg\t\n1\n1\t\n1\n1\t转氨酶升高\n注 :药物的使用方法、不良反应、适应证和禁忌证 ,详见国家药品监督管理局批准的有关药物的说明书。\n表 17   常用降压药种类的临床选择\n\n分类\t适应证\t禁忌证\n\t\t绝对禁忌证\t相对禁忌证\n二氢吡啶类 CCB\t　老年高血压 周围血管病\n单纯收缩期高血压 稳定性心绞痛\n颈动脉粥样硬化\n冠状动脉粥样硬化\t无\t快速型心律失常 心力衰竭\n非二氢吡啶类 CCB\t心绞痛\n颈动脉粥样硬化\n室上性快速心律失常\t二度至三度房室传导阻滞 心力衰竭\t\nACEI\t　心力衰竭 冠心病\n左心室肥厚\n左心室功能不全 心房颤动预防\n　颈动脉粥样硬化 非糖尿病肾病\n糖尿病肾病\n　蛋白尿/微量白蛋白尿 代谢综合征\t妊娠\n高血钾\n双侧肾动脉重度狭窄\t\nARB\t糖尿病肾病\n蛋白尿/微量白蛋白尿 冠心病\n心力衰竭\n左心室肥厚\n心房\n######################\nOutput:", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": 4000, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_54c96ba750b88441c639d8bf385e904a8d1853f6c55abd67ebf5b6ec3efcfc9d_v2"}